Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

被引：32
|
作者：
Speer, Michael E. [1 ]
Fernandes, Caraciolo J. [1 ]
Boron, Marnie [2 ]
Groothuis, Jessie R. [2 ]
机构：
[1] Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
[2] Medimmune Inc, Gaithersburg, MD 20878 USA
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2008年 / 27卷 / 06期
关键词：
cystic fibrosis; RSV; palivizumab; hospitalization;
D O I：
10.1097/INF.0b013e3181673c15
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received >= 1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.
引用
下载
收藏
页码：559 / 561
页数：3
相关论文
共 50 条
  • [21] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections
    Abramson, JS
    Baker, CJ
    Baltimore, RS
    Bocchini, JA
    Long, SS
    McMillan, JA
    Meissner, HC
    Powell, KR
    Prober, CG
    Rennels, MB
    Saari, TN
    Weiner, LB
    Blackmon, L
    Batton, DG
    Bell, EF
    Denson, SE
    Engle, WA
    Kanto, WP
    Martin, GI
    Stark, AR
    PEDIATRICS, 2003, 112 (06) : 1447 - 1452
  • [22] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    Null, D
    Bimle, C
    Weisman, L
    Johnson, K
    Steichen, J
    Singh, S
    Wang, E
    Asztalos, E
    Loeffler, AM
    Azimi, PH
    Lieberman, JM
    O'Donnell, NE
    Cooke, RJ
    McCormick, K
    Koo, W
    Hammami, M
    Milner, AD
    Gaon, P
    Nachman, S
    Tarpey, KP
    Sánchez, PJ
    Broyles, RS
    Bratcher, D
    Ball, MV
    Duda, FJ
    DeCuir, PM
    Pollara, B
    Nelson, LS
    Balbus, M
    Schultz, MJ
    Chipps, BE
    Givner, LB
    O'Shea, M
    Everard, M
    Pfeffer, K
    Page, AJ
    Dennehy, PH
    Modlin, J
    Rhodes, T
    DeVincenzo, N
    Nickerson, B
    Arrieta, A
    Boucher, FD
    Keeney, RE
    Young, TE
    Stevens, JC
    Ariagno, R
    Adams, M
    Polak, MJ
    Lynch, SK
    PEDIATRICS, 1998, 102 (03) : 531 - 537
  • [23] The frequency of respiratory syncytial virus in high risk infants and the role of palivizumab in prevention of infection
    Tom, CM
    Touch, SM
    Stanley, C
    Frey, B
    McNett, W
    Desai, SA
    PEDIATRICS, 1999, 104 (03) : 736 - 737
  • [24] Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016)
    Ian Mitchell
    S. K. Wong
    B. Paes
    M. Ruff
    C. Bjornson
    A. Li
    K. L. Lanctôt
    European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1345 - 1352
  • [25] Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants
    Banerji, Anna
    Lanctot, Krista L.
    Paes, Bosco A.
    Masoud, Shababa T.
    Tam, Derrick Y.
    Macdonald, W. Alexander
    Roberts, Ann
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) : 702 - 706
  • [26] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [27] The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
    Speer, Michael E.
    Good, Amy B.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 459 - 469
  • [28] Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland
    Groves, H. E.
    Jenkins, L.
    Macfarlane, M.
    Reid, A.
    Lynn, F.
    Shields, M. D.
    PEDIATRIC PULMONOLOGY, 2016, 51 (04) : 379 - 385
  • [29] Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016)
    Mitchell, Ian
    Wong, S. K.
    Paes, B.
    Ruff, M.
    Bjornson, C.
    Li, A.
    Lanctot, K. L.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (07) : 1345 - 1352
  • [30] Immunoprophylaxis with palivizumab for prevention of Respiratory Syncytial Virus infection: Indications for use and preliminary data
    Vagnarelli, F
    Vancini, A
    Mariani, S
    Magnani, C
    Banchini, G
    PERINATOLOGY 2001, VOLS 1 AND 2, 2001, : 1001 - 1003
12345